Back to catalogue
№ 164 47 filings · 2021-09-27 → 2026-08-03

ELIXIRR INTERNATIONAL PLC

ELIX
Industrial Goods and Services Share price 608p Market cap £297m Overall fit 720 /1000

Direct and quantified AI-consulting exposure, genuine operating leverage from a Partner-plus-central-cost model, and a fair (arguably cheap) valuation after the recent de-rating — offset only by consulting cyclicality and an acquisition-heavy earnings signal that reduces earnings-quality clarity.

Fair value range 850p–1,100p Mid case · £484m
Absolute upside +62.8% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • Five-year track record of beat-or-meet with 28-31% Adj EBITDA margins
  • Clear disclosure and reconciliations to non-GAAP measures
  • H1 26 acceleration (revenue +25%, margin +100bps) confirms operating leverage thesis
Limits the call
  • Contingent-consideration accounting creates statutory P&L volatility
  • Limited independent disclosure on post-acquisition performance of TRC/Kvadrant
Methodology

Forward EV/Adj EBITDA multiple (9-12x FY26E) with soft DCF cross-check

In one line · bull case

Fast-growing challenger consultancy with quantified AI-enabler revenue and 30%+ EBITDA margins now available on ~7x forward EV/EBITDA after a 30% share-price de-rating.

In one line · biggest risk

Programmatic M&A engine leaves the P&L exposed to contingent-consideration swings and any integration slippage at recent large deals (TRC, Kvadrant).

Drivers
AI beneficiary 75 /100
Direct AI-consulting revenue up 260% in FY25 with iOLAP/Responsum embedded; classified as AI enabler in the picks-and-shovels bucket, though still IT-services rather than pure infrastructure.
Operating leverage 65 /100
Revenue-per-Partner up ~30% since IPO and H1 26 saw 100bps margin expansion on 25% growth; capacity-constrained services with fixed central overhead, but not pure software.
Earnings vs expectations 75 /100
Consistent beat-or-meet pattern across FY22-FY25 with two mid-year FY23 upgrades; no visible profit warnings in the filings.
Growth momentum 80 /100
Accelerating: FY25 revenue +34%, H1 26 revenue +25% organic-plus-M&A with three consecutive record quarters and 260% AI revenue growth.
Moat 45 /100
Brand and Partner-network execution moat rather than structural; switching costs are engagement-level, not platform-level.
Earnings quality 60 /100
Cash conversion is strong (FY24 FCF +74% vs prior year) but heavy use of Adjusted metrics and material contingent-consideration remeasurement create some noise between statutory and adjusted profits.
Management quality 75 /100
Founder-led (Newton), disciplined capital allocation (nine acquisitions at reasonable multiples, no dilutive placings for M&A), Chairman is Gavin Patterson (ex-BT/Salesforce).
Cyclicality 55 /100
Consulting is moderately cyclical, exposed to corporate discretionary spend, but diversified across nine industries and three regions.
Leverage 30 /100
Modest net debt of £24m at FY25 with £65m RCF + US$20.25m term loan headroom; comfortably below 1x EBITDA.

ELIXIRR INTERNATIONAL PLC (ELIX) — Investment Research Note

Executive summary

Elixirr is a UK-listed global "challenger" management consultancy that combines strategy, digital, data and AI services with a programmatic M&A engine (nine acquisitions since AIM IPO in 2020) and a highly-incentivised Partner model. Across FY20–FY25 the Group has grown revenue at ~40% CAGR (£30m → £149m) while sustaining ~28-31% Adjusted EBITDA margins, achieving "Rule of 40" every year since IPO and Rule of 50 in FY24 and FY25 2026-01-22 trading update. The single most important valuation point today: the shares have de-rated ~30% from 52-week highs to c.626p, putting the stock on ~7-8x FY25 EV/Adj EBITDA and mid-single-digit forward FY26 EV/EBITDA despite Q1 and Q2 2026 both being record quarters with 25% H1 revenue growth and 260%+ AI revenue growth in FY25.

Fair value estimate

  • Fair value range: 850p – 1,100p per share → implied market cap range £422m – £546m.
  • Methodology: forward EV/Adj EBITDA multiple triangulated with a soft DCF cross-check.
    • FY26E revenue (illustrative, from H1 26 £89m annualised with modest H2 acceleration and full-year TRC/Kvadrant): ~£185–195m.
    • Applying H1 26 Adj EBITDA margin of 31.0% → FY26E Adj EBITDA ~£57–60m.
    • Fair EV/Adj EBITDA multiple range: 9x–12x — reflects 20%+ growth, 30%+ margins, entrepreneurial capital-light model, but discounted for size (£300m mcap), acquisition-heavy earnings, and consulting cyclicality.
    • EV range £500–720m; deduct estimated net debt of ~£45–55m post-Kvadrant and TRC top-up → equity range £445–670m → ~900–1,350p undiluted. Adjusting downward for share-option/earn-out dilution (~4-5m potential incremental shares) and being conservative, I anchor the range at 850–1,100p.
  • Current mcap: £307.3m at 626p.
  • Absolute upside to midpoint (975p) ≈ +56%; range: +36% to +76%.

Sector context

  • ICB classification is Industrial Goods & Services (Professional/Consulting Services). Confirmed appropriate — Elixirr is a technology-enabled management consultancy.
  • Quality profile: above sector. 28-31% Adj EBITDA margins compare favourably vs. listed IT-services peers (Accenture mid-teens, Capgemini low-teens, Endava high-teens historically), and organic growth of ~15-25% has beaten the MCA industry average of ~3-4% consistently 2025-09-22 interim results.
  • Listed peers: Accenture (ACN), Capgemini (CAP.PA), Endava (DAVA), Kainos (KNOS), Globant (GLOB), EPAM (EPAM). Elixirr trades at a discount to most of these on forward EBITDA despite superior growth-plus-margin metrics.

Investment thesis (3 bullets)

  1. Genuine, quantified AI-enabler exposure — H1 26 revenue +25% and Adj EBITDA margin up 100bps to 31.0% "with further, significant growth in AI-related revenue"; FY25 saw 260% growth in AI-related revenue, and management cites third-party research pointing to $200bn of net new AI-driven demand for tech services over five years, positioning Elixirr in the "AI enabler" bucket 2026-08-03 trading update. iOLAP (data/analytics) and Responsum (generative AI platform) acquisitions purchased at modest multiples now feed a growing cross-sell.
  2. Operating leverage is real and scaling — Revenue per Partner has grown every year since IPO (£3.15m FY21 → £4.1m FY24), £1m+ "gold clients" rose from 22 (H1 25) to 34 (FY25), and H1 26 EBITDA margin expanded 100bps on 25% revenue growth — evidence the fixed central cost base is not scaling with revenue 2026-01-22 trading update; 2026-08-03 trading update. Delivering more revenue and EBITDA in H1 26 than the whole of FY23 shows how fast the base is compounding.
  3. Priced for reality, not perfection — The stock has dropped from a 52-week high of 896p to 626p (-30%), placing it on ~7x FY25 Adj EBITDA and c.5-6x forward FY26 EV/EBITDA. Institutional appetite is visible: an £12m secondary placing at 750p was oversubscribed in April 2026, and Canaccord Genuity was appointed joint broker in August 2026 to widen the US shareholder base 2026-04-28 result of secondary placing; 2026-08-03 trading update.

Key risks (3 bullets)

  1. Acquisition digestion & contingent consideration risk — Nine deals since 2020, culminating in TRC (US$125m max) and Kvadrant (£18m max) in the last twelve months. TRC alone has US$68m of contingent earn-out, and the balance sheet moved from net cash £7.5m (FY24) to net debt £24.1m (FY25) post-TRC 2025-09-22 interim results; 2026-01-22 trading update. Integration slippage or margin dilution from newly-acquired firms could hurt.
  2. Consulting is discretionary and cyclical — Financial services and technology clients dominate the revenue mix; corporate cost-cutting cycles or a macro downturn would compress project pipelines. Two client take-overs in FY22 removed £1.9m of revenue in a single year — evidence of client concentration risk 2024-04-22 final results.
  3. Earnings quality caveat around "Adjusted" metrics — The Group makes heavy use of Adjusted EBITDA/PBT/EPS. FY24 statutory PBT grew only 4% vs. Adjusted EBITDA +23%, primarily due to swing in contingent consideration accounting. Investors should watch how the FY26 Hypothesis/TRC/Kvadrant contingent liabilities settle; a "not disclosed but inferred" risk is the potential for large non-cash P&L volatility from earn-out remeasurements.

Operating leverage

Elixirr's cost base is dominated by consulting staff (cost of sales was 67% of revenue in FY24 and H1 25) plus a modest central overhead (administrative expenses at ~10% of revenue). Roughly 45-50% of revenue is fixed-in-the-short-term (Partner and senior staff salaries, central functions, office leases, share-based payments), while the balance flexes with utilisation. The proof of the leverage is empirical: H1 25 revenue grew 35% and Adj EBITDA grew 42%; H1 26 revenue grew 25% and Adj EBITDA grew 29% with margins up 100bps. Revenue per Partner has grown ~30% since IPO. Historically the Group has held Adjusted EBITDA margin in a 28-31% band even while absorbing lower-margin acquired businesses, suggesting genuine leverage on the core. On a 10-20% revenue beat above plan, one would expect Adj EBITDA to grow at roughly 1.3-1.5x the revenue rate — meaningful, but not the "multiples of profit" one gets from pure software. Capacity constraint is the main uplift lever: each new Partner unlocks c.£2m+ of incremental revenue at high incremental margin once ramped. 2025-09-22 interim results; 2026-08-03 trading update

Value-trap signals

None identified. Growth is accelerating not decelerating (25% H1 26 vs 30% FY24), dividend is up 21% YoY, net debt is modest and self-funded from operating cash, guidance has consistently been met or upgraded, and there is no evidence of accounting aggression beyond routine contingent-consideration remeasurement. Founder-CEO Stephen Newton continues to hold ~28% and Partners collectively hold significant equity. The recent price weakness appears de-rating driven (broader sector rerating and post-Main-Market-listing settling), not fundamentals-driven.

Earnings vs. expectations

Across the filings, Elixirr has a consistent beat-or-meet track record:

  • FY22: revenue "in line with market expectations" at ~£70.7m; Adj EBITDA margin 29% above prior 27-28% guidance 2023-02-27 trading update.
  • FY23 upgraded guidance twice during the year (initial £47-50m → final £85.9m materially reflecting M&A); revenue delivered in the £85-90m guided range 2024-01-08 trading update.
  • FY24: revenue £111.3m came in above the £108-111m guided range; Adj EBITDA margin at 28% within 27-29% guidance 2025-02-18 trading update.
  • FY25: revenue expected to "meet or exceed" market expectations of £149m; EBITDA margin at or above 28.1-29.2%; year-end net debt £7m favourable to expectations 2026-01-22 trading update.
  • H1 26: revenue £89.0m +25%, EBITDA margin 31.0% (+100bps) — clearly ahead of the typical H1 seasonal pattern.

Pattern: more beats than in-line prints, no visible misses across five reporting cycles.

Conviction

Conviction: 4 / 5 — high.

Supporting factors: (i) five-year track record of consistent double-digit organic growth and stable EBITDA margins around 28-31%; (ii) audited financials with clear reconciliations to Adjusted metrics; (iii) methodology (forward EV/EBITDA) is standard for a growth consulting firm and gives a similar answer across multiple recent trading windows.

Limiting factors: (i) the earn-out and contingent-consideration liabilities on TRC, Kvadrant, Hypothesis create meaningful forward P&L volatility that could swing statutory profits ±£5-10m in any period; (ii) FY26 revenue depends on TRC hitting its FY25 EBITDA targets to trigger the top-up consideration, and there is limited public disclosure of trend since acquisition.

Filings consulted · 51

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-08-03Trading Update And Appointment OF Joint Broker2026-08-03_9699755_trading-update-and-appointment-of-joint-broker.md0.85
  2. 2026-06-30Result OF Agm2026-06-30_9644851_result-of-agm.md0.30
  3. 2026-06-02Notice OF Agm And Dividend Timetable2026-06-02_9597187_notice-of-agm-and-dividend-timetable.md0.30
  4. 2026-04-29Publication OF 2025 Annual Report2026-04-29_9544460_publication-of-2025-annual-report.md0.95
  5. 2026-04-28Result OF Secondary Placing2026-04-28_9542657_result-of-secondary-placing.md0.70
  6. 2026-04-28Proposed Secondary Placing2026-04-28_9542519_proposed-secondary-placing.md0.70
  7. 2026-03-27Notice OF FY 25 Investor Presentation2026-03-27_9495005_notice-of-fy-25-investor-presentation.md0.70
  8. 2026-02-02Acquisition OF Kvadrant Consulting A S2026-02-02_9399712_acquisition-of-kvadrant-consulting-a-s.md0.64
  9. 2026-01-22Trading Update And Interim Dividend2026-01-22_9374468_trading-update-and-interim-dividend.md0.72
  10. 2025-09-22Interim Results2025-09-22_9121794_interim-results.md0.77
  11. 2025-09-22Acquisition OF Trc Advisory Llc2025-09-22_9121527_acquisition-of-trc-advisory-llc.md0.64
  12. 2025-09-17Notice OF H1 25 Investor Presentation2025-09-17_9112327_notice-of-h1-25-investor-presentation.md0.59
  13. 2025-07-14Trading Update2025-07-14_8976526_trading-update.md0.55
  14. 2025-06-24Result OF Agm2025-06-24_8945512_result-of-agm.md0.20
  15. 2025-05-30Main Market Update Amp Capital Markets Day2025-05-30_8903844_main-market-update-amp-capital-markets-day.md0.62
  16. 2025-05-29Posting OF Annual Report And Accounts2025-05-29_8901554_posting-of-annual-report-and-accounts.md0.62
  17. 2025-05-21Capital Markets Day2025-05-21_8888725_capital-markets-day.md0.62
  18. 2025-04-28Final Results2025-04-28_8847904_final-results.md0.65
  19. 2025-03-11Notice OF Fy24 Investor Presentation2025-03-11_8772257_notice-of-fy24-investor-presentation.md0.46
  20. 2025-02-18Trading Update2025-02-18_8740536_trading-update.md0.55
  21. 2024-10-25Result OF Secondary Placing2024-10-25_8507863_result-of-secondary-placing.md0.46
  22. 2024-10-24Proposed Secondary Placing2024-10-24_8507345_proposed-secondary-placing.md0.46
  23. 2024-10-21Acquisition OF Hypothesis Group Llc2024-10-21_8497257_acquisition-of-hypothesis-group-llc.md0.49
  24. 2024-10-01Investor Presentation2024-10-01_8451841_investor-presentation.md0.46
  25. 2024-09-23Interim Results2024-09-23_8431293_interim-results.md0.58
  26. 2024-06-25Result OF Agm2024-06-25_8277034_result-of-agm.md0.14
  27. 2024-05-31Posting OF Annual Report And Accounts2024-05-31_8233238_posting-of-annual-report-and-accounts.md0.43
  28. 2024-04-22Final Results2024-04-22_8148149_final-results.md0.45
  29. 2024-04-08Notice OF FY 23 Results And Investor Presentation2024-04-08_8124553_notice-of-fy-23-results-and-investor-presentation.md0.32
  30. 2024-01-08Trading Update And Change TO Dividend Policy2024-01-08_7977896_trading-update-and-change-to-dividend-policy.md0.38
  31. 2023-12-11Acquisition OF Insigniam Llc And Insigniam Sas2023-12-11_7933218_acquisition-of-insigniam-llc-and-insigniam-sas.md0.34
  32. 2023-09-18Interim Results2023-09-18_7760444_interim-results.md0.41
  33. 2023-09-18Acquisition OF Responsum Inc2023-09-18_7760440_acquisition-of-responsum-inc.md0.34
  34. 2023-06-13Result OF Agm2023-06-13_7572356_result-of-agm.md0.07
  35. 2023-05-19Posting OF Annual Report And Accounts2023-05-19_7533787_posting-of-annual-report-and-accounts.md0.24
  36. 2023-04-03Final Results2023-04-03_7424140_final-results.md0.25
  37. 2023-03-28Investor Presentation2023-03-28_7335581_investor-presentation.md0.17
  38. 2023-02-27Trading Update2023-02-27_7235611_trading-update.md0.21
  39. 2022-11-29Investor Presentation2022-11-29_7220436_investor-presentation.md0.17
  40. 2022-09-20Interim Results2022-09-20_7369327_interim-results.md0.23
  41. 2022-09-12Notice OF Interim Results2022-09-12_7273907_notice-of-interim-results.md0.23
  42. 2022-06-13Result OF Agm2022-06-13_6938858_result-of-agm.md0.07
  43. 2022-05-19Posting OF Annual Report Amp Accounts2022-05-19_6933140_posting-of-annual-report-amp-accounts.md0.24
  44. 2022-04-29Result OF Secondary Placing2022-04-29_7139411_result-of-secondary-placing.md0.17
  45. 2022-04-28Proposed Secondary Placing2022-04-28_7089584_proposed-secondary-placing.md0.17
  46. 2022-04-04Final Results2022-04-04_7148576_final-results.md0.25
  47. 2022-03-18Acquisition OF Iolap And Fy2022 Earnings2022-03-18_6970398_acquisition-of-iolap-and-fy2022-earnings.md0.19
  48. 2022-02-01Trading Update2022-02-01_7043961_trading-update.md0.21
  49. 2021-10-13Result OF Secondary Placing2021-10-13_6768431_result-of-secondary-placing.md0.17
  50. 2021-10-13Proposed Secondary Placing2021-10-13_6766415_proposed-secondary-placing.md0.17
  51. 2021-09-27Interim Results2021-09-27_6561103_interim-results.md0.23

This research note was authored by a large language model after reading 47 regulatory filings published between 2021-09-27 and 2026-08-03. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.